**Johnson & Johnson Announces Favorable Study Results for Erleada**
Johnson & Johnson (JNJ) revealed on Wednesday that a recent head-to-head study has demonstrated a statistically significant overall survival benefit at 24 months for patients taking Erleada, compared to those on Enzalutamide, in cases of metastatic castration-sensitive prostate cancer.
The analysis highlighted that patients who began treatment with Erleada as their first-line androgen receptor pathway inhibitor experienced a statistically significant 23 percent reduction in the risk of death at 24 months, in comparison to those treated with Enzalutamide.
"Erleada is unique among ARPIs, showing a survival benefit as soon as 22 months, as evidenced by the TITAN study," stated Luca Dezzani, U.S. Vice President of Medical Affairs for Solid Tumors at Johnson & Johnson Innovative Medicine.
As of the latest trading session, JNJ's stock is priced at $161.06, reflecting a 0.57 percent decrease on the New York Stock Exchange.
